Abstract

Abnormalities in GABAergic inhibitory circuits have been implicated in the aetiology of autism spectrum disorder (ASD). ASD is caused by genetic and environmental factors. Several genes have been associated with syndromic forms of ASD, including FOXG1. However, when and how dysregulation of FOXG1 can result in defects in inhibitory circuit development and ASD-like social impairments is unclear. Here, we show that increased or decreased FoxG1 expression in both excitatory and inhibitory neurons results in ASD-related circuit and social behavior deficits in our mouse models. We observe that the second postnatal week is the critical period when regulation of FoxG1 expression is required to prevent subsequent ASD-like social impairments. Transplantation of GABAergic precursor cells prior to this critical period and reduction in GABAergic tone via Gad2 mutation ameliorates and exacerbates circuit functionality and social behavioral defects, respectively. Our results provide mechanistic insight into the developmental timing of inhibitory circuit formation underlying ASD-like phenotypes in mouse models.

Cortical excitatory/inhibitory (E/I) imbalance is a feature of autism spectrum disorder (ASD). Here, the authors show that FoxG1 regulates the formation of cortical GABAergic circuits affecting social behaviour during a specific postnatal time window in mouse models of ASD.

Details

Title
FoxG1 regulates the formation of cortical GABAergic circuit during an early postnatal critical period resulting in autism spectrum disorder-like phenotypes
Author
Miyoshi Goichi 1   VIAFID ORCID Logo  ; Ueta Yoshifumi 1 ; Natsubori Akiyo 2   VIAFID ORCID Logo  ; Hiraga Kou 1   VIAFID ORCID Logo  ; Osaki Hironobu 1   VIAFID ORCID Logo  ; Yagasaki Yuki 1 ; Kishi Yusuke 3   VIAFID ORCID Logo  ; Yanagawa Yuchio 4 ; Fishell Gord 5 ; Machold, Robert P 6 ; Miyata Mariko 1   VIAFID ORCID Logo 

 Tokyo Women’s Medical University, Department of Neurophysiology, Shinjuku, Japan (GRID:grid.410818.4) (ISNI:0000 0001 0720 6587) 
 Sleep Disorders Project, Tokyo Metropolitan Institute of Medical Science, Setagaya, Japan (GRID:grid.272456.0) 
 Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X) 
 Gunma University Graduate School of Medicine, Department of Genetic and Behavioral Neuroscience, Maebashi, Japan (GRID:grid.256642.1) (ISNI:0000 0000 9269 4097) 
 NYU Neuroscience Institute, Smilow Research Center, New York University School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); Harvard Medical School, Department of Neurobiology, Blavatnik Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Stanley Center at the Broad Institute, Cambridge, USA (GRID:grid.66859.34) 
 NYU Neuroscience Institute, Smilow Research Center, New York University School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2542532313
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.